United States · FDA National Drug Code directory
deferasirox
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 62756-569_88009dbf-bf02-432b-95d4-27a6934590b8
- Product NDC
- 62756-569
- Form
- TABLET, FOR SUSPENSION
- Composition / generic term
- deferasirox
- Labeler
- Sun Pharmaceutical Industries, Inc.
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20191202
- Source listing expiry
- 20261231
Source-listed ingredients
- DEFERASIROX — 250 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-569-83) · 62756-569-83
- 60 TABLET, FOR SUSPENSION in 1 BOTTLE (62756-569-86) · 62756-569-86
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →